Shares of GenFleet Therapeutics (02595.HK) soared an impressive 115.60% in their Hong Kong stock market debut on Friday, reflecting robust investor enthusiasm for the biopharmaceutical company. The stock opened at HK$44 per share, more than double its initial public offering (IPO) price of HK$20.39, showcasing strong market confidence in the firm's potential.

The remarkable debut follows an overwhelmingly successful IPO, which raised approximately HK$1.67 billion in net proceeds. The offering saw extraordinary demand, with the Hong Kong public offering portion oversubscribed by a staggering 2,662.79 times. The international offering also garnered significant interest, being oversubscribed 39.05 times. This level of oversubscription underscores the high expectations investors have for GenFleet's future prospects in the competitive biotech sector.

GenFleet Therapeutics, focusing on novel treatments in oncology, autoimmune, and inflammatory diseases, has established a pipeline of eight product candidates, with five currently under clinical development. The company plans to allocate 71% of the IPO proceeds to further develop its two core products, demonstrating its commitment to advancing its research and development efforts. Despite reporting an expanded net loss of HK$677.6 million in the previous year, the firm's revenue grew by 42% to HK$104.7 million, indicating potential for future growth. As GenFleet Therapeutics embarks on its journey as a public company, investors will be closely watching its ability to capitalize on the booming healthcare sector and deliver on its promising pipeline.